Archive for October, 2008

Zetia and Vytorin: Let’s Look at the Facts

Thursday, October 30th, 2008

Let’s talk about the current media frenzy about the results of a study that seems to conclude that Zetia may not be effective for treating high cholesterol: the ENHANCE study. After the reports were published, I got a bunch of telephone calls from patients and family who are either on Vytorin or on Zetia in combination with another statin and they want to know about what to do now.My response to them is to relax, and please read this post. I…

Business Wire - Niaspan® Combined with Low/Moderate Dosed Statin Achieves Better Total Lipid Control vs. Higher Dose Statin Monotherapy or Zocor

Sunday, October 26th, 2008

CRANBURY, N.J. — Kos Pharmaceuticals, Inc. (Nasdaq: KOSP):
–COMPELL study shows significantly greater reductions in triglycerides and Lp(a), as well as superior 2.5-3.5 fold increases in HDL-C and comparable lowering of LDL-C with Niaspan combination therapy versus Crestor(R) and Zocor/Zetia

Business Wire - New Analysis in Patients with Type 2 Diabetes from Trial with VYTORIN-TM- -ezetimibe/simvastatin- Presented at ADA; Consistent with Overall Study which Showed…

Thursday, October 23rd, 2008

PHILADELPHIA — According to research from Cognet-X, Inc., conducted after Merck/Schering-Plough released its ENHANCE study results, pharmacy and medical executives at managed health care companies see few immediate changes in how their organizations cover the cholesterol reducers Vytorin and Zetia.
However, utilization of the brands is expected to decrease after ENHANCE showed that Vytorin - a combination of the statin simvastati…

Lipitor – Now Available Online to Lower Your Cholesterol Levels

Saturday, October 18th, 2008

Cholesterol problems generally ignored by people can lead to serious consequences if not attended at the right time. Lipitor, including lipitor pravachol, pravachol lipitor or lipitor zetia is a perfect medication recommended by doctors to k…

PR Newswire - Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck

Wednesday, October 15th, 2008

Lawsuit claims manufacturers misled consumers about the use of Zetia and Vytorin.
SEATTLE, June 10 /PRNewswire/ — Last week the U.S. District Court in New Jersey appointed Hagens Berman, along with four other firms, co-counsel in a case against Schering-Plo…

U.S. Newswire - African Americans Should Not Stop Taking Vytorin or Zetia Without Consulting Their Healthcare Providers

Saturday, October 11th, 2008

To: MEDICAL EDITORS

Contact: Keith Ferdinand, MD, 1-404-201-6632

ATLANTA, Jan. 24 /PRNewswire/ — The recent release of the
ENHANCE study of Vytorin and Zetia has drawn considerable media
attention, but stopping cholesterol medications based on this study
alone is not appropriate. The…

M2 Presswire - Understand how Schering-Ploughs ethical sales are set to grow at a 2004-2010 CAGR of 7.4%, driven by Remicade, Zetia/Vytorin and the Intron franchise.

Wednesday, October 8th, 2008

M2 PRESSWIRE-15 February 2006-Research and Markets: Understand how Schering-Ploughs ethical sales are set to grow at a 2004-2010 CAGR of 7.4, driven by Remicade, Zetia/Vytorin and the Intron franchise(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:15022006 Dublin - Research and Mark…

USA TODAY - Vytorin, Zetia should be drugs of last resort, panel urges

Saturday, October 4th, 2008

CHICAGO — The blockbuster drugs Vytorin and Zetia should be used only after all other cholesterol-lowering drugs fail until research proves that the medications work, a panel of heart specialists recommended here Sunday.

The panel, convened by the American College of Cardiology, based its assessment on detailed evidence from a controversial study, released Sunday, showing that Vytorin worked no better than a statin drug now sold as a cheap generic.

“There is…

Business Wire - Research and Markets: Determine the Impact of the ENHANCE Study on Vytorin and Zetia Use

Wednesday, October 1st, 2008

DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/research/4e90d7/vytorin_wave_two) has announced the addition of the “Vytorin: Wave Two - Impact of ENHANCE Trial” report to their offering.
A Survey of One-Hundred Three US-based PCP’s and Cardiologists
Deliverable: Survey with key findings.
Study Description:
Topic: Vytorin: Wave …